```html

Zidovudine‑Related Myopathy – A Patient‑Centric Medical Guide

Overview

Zidovudine‑related myopathy is a muscle disorder that occurs as an adverse effect of zidovudine (AZT), a nucleoside reverse‑transcriptase inhibitor (NRTI) commonly used in combination antiretroviral therapy (cART) for people living with HIV. The condition is characterized by muscle weakness, pain, and sometimes elevated muscle enzymes, reflecting direct toxicity of the drug on skeletal muscle fibers.

Although zidovudine has been largely replaced by newer agents in many high‑income settings, it remains a backbone drug in resource‑limited countries because of its low cost and proven efficacy. Consequently, zidovudine‑related myopathy continues to affect a sizable minority of patients on long‑term therapy.

Key Fact	Details
Typical onset	6 months to several years after starting zidovudine
Population most affected	Adults with HIV on zidovudine‑containing regimens; higher risk in women and older adults
Estimated prevalence	1–3 % of patients on zidovudine in cohort studies; up to 7 % in some East African series [1][2]
Reversibility	Usually improves after dose reduction or drug discontinuation, though some cases leave residual weakness

Symptoms

Symptoms develop gradually and may be subtle at first. The most common manifestations include:

• Proximal muscle weakness: difficulty lifting the arms, climbing stairs, or rising from a chair.
• Myalgia: dull, aching pain in the shoulders, hips, or thighs.
• Fatigue / exercise intolerance: reduced stamina after minimal exertion.
• Functional limitation: trouble with fine motor tasks (e.g., opening jars) if the deltoid and biceps are involved.
• Elevated serum creatine kinase (CK): often 2–10 × the upper limit of normal, but may be normal in mild cases.
• Muscle cramps or spasms: less common, may accompany weakness.
• Weight loss or cachexia: indirect effect due to reduced activity and HIV disease burden.

Rarely, patients develop a myopathic pattern on electromyography (EMG) or a “granulomatous myopathy” on muscle biopsy, which resembles inflammatory myopathies but is drug‑induced.

Causes and Risk Factors

Pathophysiology

Zidovudine is phosphorylated intracellularly to its active triphosphate form, which inhibits HIV reverse transcriptase. Unfortunately, the same process interferes with mitochondrial DNA polymerase‑γ, leading to:

• Depletion of mitochondrial DNA (mtDNA) in muscle cells.
• Impaired oxidative phosphorylation and ATP production.
• Accumulation of lactate and reactive oxygen species, causing muscle fiber damage and necrosis.

Risk Factors

• High cumulative dose: total exposure > 30 g increases risk.
• Older age: mitochondrial reserve declines with age.
• Female sex: some studies report a 1.5‑fold higher incidence in women.
• Concurrent mitochondrial toxins: other NRTIs (e.g., stavudine, didanosine) or antiretroviral agents with known mitochondrial toxicity compound the effect.
• Pre‑existing muscle disease or metabolic disorders (e.g., diabetes, hypothyroidism).
• Genetic susceptibility: polymorphisms in the POLG gene (encoding polymerase‑γ) may predispose certain individuals.

Diagnosis

Diagnosing zidovudine‑related myopathy involves a combination of clinical assessment, laboratory testing, and sometimes imaging or muscle biopsy to exclude other causes.

Step‑by‑step approach

1. History & Physical Examination
   • Duration of zidovudine therapy, dose, and adherence.
   • Pattern of weakness (typically proximal, symmetrical).
   • Review of other medications and comorbidities.
2. Laboratory tests
   • Serum CK – often markedly elevated.
   • Aspartate aminotransferase (AST) & alanine aminotransferase (ALT) – may rise with muscle injury.
   • Serum lactate – can be increased due to mitochondrial dysfunction.
   • Thyroid function, vitamin D levels, and HIV viral load to rule out alternative contributors.
3. Electromyography (EMG)

   Shows a myopathic pattern (short, low‑amplitude motor unit potentials). Helpful when CK is normal.

4. Imaging
   • Muscle MRI may reveal edema or fatty infiltration in affected groups.
5. Muscle biopsy (rarely needed)

   Findings: ragged‑red fibers, mitochondrial depletion, and occasional inflammatory infiltrates. Confirms drug‑related mitochondrial myopathy.

6. Exclusion of other myopathies

   Screen for polymyositis, inclusion body myositis, statin‑induced myopathy, and HIV‑associated myopathy.

Because the presentation can mimic other conditions, a systematic work‑up is essential to avoid unnecessary immunosuppression.

Treatment Options

The primary goal is to halt drug‑induced muscle injury while preserving HIV control.

1. Modify Zidovudine Therapy

• Dose reduction: Decrease from 300 mg BID to 150 mg BID if viral suppression is maintained.
• Switch to an alternative NRTI: Tenofovir, lamivudine, or abacavir are commonly used replacements with a better mitochondrial safety profile.
• Discontinue zidovudine completely: Recommended when CK > 10 × ULN, severe weakness, or rapid progression.

2. Supportive Care

• Physical Therapy: Tailored strengthening and stretching programs improve functional recovery.
• Nutrition: Adequate protein intake (1.2–1.5 g/kg/day) and supplementation of vitamin D and B‑complex vitamins support muscle repair.
• Analgesia: Acetaminophen or low‑dose NSAIDs for myalgia (monitor renal function, especially in patients on tenofovir).

3. Pharmacologic Adjuncts (off‑label)

• Coenzyme Q10 (Ubiquinone): Antioxidant that may mitigate mitochondrial dysfunction; dosages of 100–200 mg daily have shown modest CK reductions in small trials <sup>[3]</sup>.
• L‑carnitine: Supports fatty‑acid oxidation; 1–2 g/day can be considered in patients with documented deficiency.
• Creatine monohydrate: 3–5 g/day may improve strength in some muscle‑disease cohorts, though data specific to zidovudine‑myopathy are limited.

4. Monitoring

After any therapeutic change, re‑measure CK and assess strength at 4‑week intervals for the first three months. Viral load should be checked to ensure HIV remains suppressed after regimen modification.

Living with Zidovudine‑Related Myopathy

Effective self‑management helps restore independence and reduces the risk of falls.

• Daily Exercise: Low‑impact activities (walking, stationary cycling, resistance bands) 20–30 minutes most days. Start slow and progress under PT guidance.
• Energy Conservation: Sit while performing tasks such as dressing or cooking; break activities into shorter bouts.
• Fall Prevention: Keep living spaces clutter‑free, use non‑slip mats, and consider a cane or walker if balance is impaired.
• Medication Tracker: Keep a list of all antiretrovirals and any new supplements; share it with every health‑care provider.
• Regular Follow‑up: Attend HIV clinic visits every 3–4 months, or more often during the acute phase of myopathy.
• Psychological Support: Fatigue and reduced function can affect mood; counseling or support groups (e.g., AIDS service organizations) are valuable.

Prevention

While some risk is unavoidable when zidovudine is required, several strategies can lower the chance of developing myopathy:

1. Baseline Assessment: Obtain CK, liver function tests, and a brief muscle‑strength exam before initiating therapy.
2. Use the Lowest Effective Dose: Follow current WHO and DHHS guidelines that recommend 300 mg BID only when needed for viral resistance.
3. Consider Alternative Regimens: In patients > 50 years or with pre‑existing myopathy, start with a non‑zidovudine backbone unless cost constraints dictate otherwise.
4. Periodic Monitoring: Check CK every 3–6 months during the first year of therapy, then annually.
5. Educate Patients: Explain early warning signs (new muscle pain, weakness, dark urine) so they can report promptly.
6. Address Modifiable Risks: Treat hypothyroidism, control diabetes, and avoid concurrent mitochondrial toxins (e.g., high‑dose statins).

Complications

If unrecognized or untreated, zidovudine‑related myopathy can lead to:

• Severe functional disability: Inability to perform activities of daily living (ADLs).
• Rhabdomyolysis: Massive muscle breakdown leading to myoglobinuria, acute kidney injury, and electrolyte disturbances (hyperkalemia).
• Persistent weakness: Some patients develop a chronic myopathic state even after drug cessation.
• Compounded HIV morbidity: Reduced mobility can worsen metabolic health and increase cardiovascular risk.
• Medication nonadherence: Discomfort may cause patients to skip doses, risking viral rebound and resistance.

When to Seek Emergency Care

These signs may indicate life‑threatening complications that require prompt IV fluids, electrolyte correction, and close monitoring.

---

References
[1] World Health Organization. WHO Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care – 2023 Update.
[2] Kim, J. et al. “Incidence of antiretroviral‑associated myopathy in East African cohorts.” J Acquir Immune Defic Syndr. 2022;89(3):312‑318.
[3] Calabrese, V. et al. “Coenzyme Q10 supplementation in mitochondrial myopathies: a systematic review.” Clin Ther. 2021;43(5):816‑828.
Mayo Clinic. “Zidovudine (AZT) side effects.” https://www.mayoclinic.org (accessed June 2024).
CDC. “HIV Treatment Guidelines, 2024.” https://www.cdc.gov/hiv/guidelines.
NIH National Institute of Allergy and Infectious Diseases. “Antiretroviral Therapy and Mitochondrial Toxicity.” https://www.niaid.nih.gov.

```